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Glucocorticoids near term are known to upregulate many im-
portant enzyme systems prior to birth. Glutamate dehydroge-
nase (GDH) is a mitochondrial enzyme that catalyzes both the
reversible conversion of ammonium nitrogen into organic ni-
trogen (glutamate production) and the oxidative deamination of
glutamate resulting in 2-oxoglutarate. The activity of this en-
zyme is considered to be of major importance in the develop-
ment of catabolic conditions leading to gluconeogenesis prior
to birth. Ovine hepatic GDH mRNA expression and activity were
determined in near-term (130 days of gestation, term 147 ± 4
days) control and acutely dexamethasone-treated (0.07 mg−1
hr−1 for 26 hr) fetuses. Dexamethasone infusion had no effect
on placental or fetal liver weights. Dexamethasone infusion for
26 hr significantly increased hepatic GDH mRNA expression.
This increased GDH mRNA expression was accompanied by an
increase in hepatic mitochondrial GDH activity, from 30.0 ± 7.4
to 58.2 ± 8.1 U GDH/U CS (citrate synthase), and there was a
significant correlation between GDH mRNA expression and
GDH activity. The generated ovine GDH sequence displayed
significant similarity with published human, rat, and murine
GDH sequence. These data are consistent with the in vivo stud-
ies that have shown a redirection of glutamine carbon away
from net hepatic glutamate release and into the citric acid cycle
through the forward reaction catalyzed by GDH, i.e., glutamate
to oxoglutarate. Exp Biol Med 228:100–105, 2003
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The mitochondrial enzyme glutamate dehydrogenase(GDH; EC 2.1.14) catalyzes both the reversible con-version of ammonium nitrogen into organic nitrogen
(glutamate production) and the oxidative deamination of
glutamate, resulting in 2-oxoglutarate. The equilibrium of
the enzyme favors the reverse reaction, the formation of
glutamate under standard conditions (1, 2). This reverse
reaction is the only pathway by which ammonia can become
bound to the -carbon of a -carboxylic acid.
GDH activity has been documented for different physi-
ological states, and in the myometrium, placenta, and fetal
liver, brain, kidney, heart, and pancreas (3–11). The present
study was stimulated by a number of studies directed at
glutamine and glutamate exchange between the fetal liver
and placenta (12, 13). These studies have shown that during
ovine fetal life, glutamine, from maternal plasma, is trans-
ported across the placenta into the fetal circulation, from
which it is taken up by the fetal liver in large quantities
(14–16). The glutamine is used in part for net fetal gluta-
mate release from the liver. The hepatic glutamate released
maintains the fetal glutamate concentration and is the key
determinant of glutamate delivery to the placenta. The pla-
centa virtually clears all the glutamate from the fetal circu-
lation, with an extraction coefficient of 75%–90% (12), and
oxidizes it through the actions of placental GDH (12, 17).
Recent studies have shown that a fetal dexamethasone in-
fusion, sufficient to induce parturition, near term also causes
a marked reduction in the net release of glutamate from the
fetal liver. Using L-[1-13C]glutamine, it was shown that the
glutamine carbon flux was redirected into the citric acid
cycle, suggesting increased placental GDH activity under
these conditions (13). The present study was designed to
determine whether there was an increased expression of
hepatic GDH mRNA and corresponding GDH activity after
such a fetal dexamethasone infusion in the near-term ovine
fetus.
Material and Methods
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Care and Use Committee. Twelve time-mated 2- to 3-year-
old Columbia-Rambouillet ewes pregnant with a single fe-
tus were used. Surgery was performed to insert catheters for
dexamethasone infusion at approximately 120 days of ges-
tation (term 147 ± 4 days). Preoperatively, the ewe was
given 500 mg of ampicillin and 500 mg of gentamycin
intramuscularly. Surgery was performed under a combina-
tion of general pentobarbital (65 mg/ml) and spinal anes-
thesia (2 ml of 1% pontocaine) after a 48-hr fast with free
access to water. During surgery, general anesthesia was
maintained with intermittent i.v. infusion of pentobarbital
via the jugular catheter. The fetus was anesthetized with
pentobarbital via the maternal circulation. The uterus was
exposed via a midline laparotomy incision. A 7- to 9-cm
uterine incision was then made, a fetal forelimb was exte-
riorized, and an incision was made on the medial site of the
knee joint. The brachial vein was located and a polyvinyl
catheter (1.4 mm OD) was inserted. An amniotic catheter
was also attached to the fetus by attachment to the brachial
vein catheter for the injection of antibiotics into the amni-
otic cavity. The catheters were flushed every other day with
heparinized saline (30 U/ml). At least 5 days were allowed
for full recovery as assessed by normal O2 content and
glucose concentration in the fetal circulation before dexa-
methasone infusion was commenced.
Experimental Design. On the day of study, at ap-
proximately 130 days of gestation, a bolus of 0.2 mg of
dexamethasone was administered to the fetus via the fetal
brachial vein followed by a continuous infusion (0.07 mg−1
hr−1) for 26 hr. This infusion rate and duration was based
upon previous studies that concluded that this regime was
sufficient to induce metabolic changes that were consistent
with the onset of parturition (18). A group of five ewes
comprised the control group. These animals had undergone
fetal surgery for use in other studies, but problems with
catheter patency made them unsuitable for their planned
studies and thus available as controls in this study. After the
experimental period, the fetus was delivered by cesarean
section with i.v. pentobarbital anesthesia (25 mg/kg). The
fetal liver was collected and weighed. The right lobe was
removed and the left lobe was sectioned into slices after
trimming the peripheral tissues. Approximately 10 g were
placed in mitochondrial isolation medium (IM) buffer (220
mM mannitol, 70 mM sucrose, 2 mM Hepes, and 0.5 mg/ml
bovine serum albumin [BSA], pH 7.4; 4°C) for mitochon-
drial fraction isolation, which proceeded immediately. Mi-
tochondria, for GDH activity determination, were obtained
as previously described (19). Mitochondrial pellets were
resuspended in IM buffer and were stored at −80°C. GDH
activity was measured within 3 weeks of mitochondrial pel-
let preparation. The remaining liver slices were frozen in
liquid nitrogen and were stored at −80°C until later total
cellular RNA extraction.
Enzymatic Analysis. The catalytic activity of GDH
was determined at room temperature by measuring the de-
crease in absorbance due to the oxidation of NADH (20).
Briefly, mitochondrial samples were thawed on ice, diluted
1:1 with IM, sonicated, and centrifuged at 100,000g for 1 hr
at 4°C. The supernate was further diluted 1:20 with IM prior
to assay. Ten to 50 l of diluted sample was added to a
reaction mixture (64.5 mM TEA, 3.22 mM EDTA, 129 mM
ammonium acetate, pH 8.0, 17.6 mM NADH, 96 mM ADP,
and 160 kU/l LDH). Absorbance was read at 339 nm until
all endogenous pyruvate had been consumed. Once a steady
state had been achieved, 100 l of 2-oxoglutarate (7 mM)
was added and changes in absorbance (OD) were recorded
every 30 sec for up to 5 min. Sample volumes that produced
a linear decrease in absorbance no greater than 0.05/min
over the 5-min oxidation period were used. NADH oxida-
tion was linear with time and enzyme concentration under
conditions reported in the original method (20). Samples
were also assayed for citrate synthase (CS) activity as pre-
viously described (21). GDH activity was than expressed as
units of GDH activity/units of CS activity, where a unit was
defined as the change in OD per minute at 25°C.
GDH Reverse Transcription-Polymerase Chain
Reaction (RT-PCR). An ovine GDH cDNA probe was
generated through RT-PCR. PCR primers were chosen
based on published sequences of the human and rat GDH
(X07769 and X14223, respectively): upper primer 5−GC-
GAGGACGACCCCAACTT-3 and lower primer, 5–
TCAATGCCAGGACCAATAA-3. The RT reaction was
carried out using 1 g of ovine liver total cellular RNA
(tcRNA) using SuperScriptII (Gibco-BRL, Gaithersburg,
MD). Thermal cycling using Taq DNA polymerase in-
cluded 35 cycles at 94°C for 1 min, annealing at 60°C for 1
min, and extension at 72°C for an additional 1 min. The
PCR reaction was held at 72°C for a final extension for 10
min before being cooled to room temperature. An aliquot of
the product was fractionated on a 1.5% agarose gel and was
stained with ethidium bromide. Liver tcRNA samples
yielded a single product of approximately 480 base pairs.
After PCR, the product was cloned into pCR 2.1 (Invitro-
gen, Carlsbad, CA) and was then transformed using a
INVF’ One Shot kit (Invitrogen).
Sequencing Data. Sequencing of the DNA was
conducted on several clones using an ABI 377 automated
DNA sequencer with dye rhodamine terminator chemistry
using both the M13 Reverse and M13 forward primers.
Nucleotide sequence verification was performed using basic
local alignment search tool (BLAST; National Center for
Biotechnology Information, Bethesda, MD). The amplified
product sequenced corresponded to nucleotides 192–672 of
human GDH (X07769) and was submitted to GenBank (ac-
cession number AY102935).
RNA Preparation and Northern Hybridiza-
ion. Total cellular RNA was prepared using TRI-
REAGENT (Molecular Resource Center, Cincinnati, OH)
as previously described (22). Total cellular RNA (20 g)
was denatured and electrophoresed in a 1% agarose gel,
glyoxal/DMSO in 0.01 M PO4 buffer (pH 7.4) and was
transferred to an N+ Hybond membrane (Amersham, Pis-
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cataway, NJ) using a pressure blotter PosiBlot (Stratagene,
La Jolla, CA) under alkaline conditions (10 mM NaOH).
After transfer, membranes were UV crosslinked and rinsed
in 6× SSC (0.72 M NaCl, 40 mM Na2HPO4.7H2O, and 4
mM EDTA) before the integrity of RNA and transfer effi-
cacy was confirmed by methylene blue staining (23). The
membranes were then rinsed in diethyl pyrocarbonate-
treated water until the membrane was clear of background
stain. These procedures were conducted at room tempera-
ture. Stained membranes were photographed, and samples
not displaying distinct and clear 28S and 18S rRNA were
discarded.
Transferred membranes were prehybridized (6× SSC,
50% [v/v] formamide, 10% [w/v] sulfate Dextran, 7% [w/v]
sodium dodecyl sulfate [SDS], 5 g/ml denatured salmon
sperm DNA, and 100 5 g/ml yeast tRNA (Gibco-BRL) for
2–4 hr at 42°C. Membranes were then hybridized with a 481
base pair EcoRI-EcoRI 32P-labeled ovine-specific GDH
cDNA fragment at a concentration of 1–2 × 106 cpm/ml.
After a 16-hr hybridization period at 42°C, membranes were
washed twice with 2× SSC/0.1% SDS for 20 min at room
temperature and then twice with 0.1× SSC/0.1% SDS for 15
min each at 65°C. The molecular size of ovine GDH-
specific band was estimated from a 0.4- to 9.5-kb RNA
ladder (Gibco-BRL). Each gel was run with a sample of
postnatal lamb and maternal liver, which served as a posi-
tive control for GDH expression. Membranes were exposed
to a phosphorus plate for 12 hr and were scanned by a Storm
system (Molecular Dynamics, Sunnyvale, CA). Resulting
images were analyzed through ImageQuant (Molecular Dy-
namics) generating data in the form of mRNA expression
volumes. To correct for loading and transfer differences
after GDH quantification, the membranes were stripped
(0.5% boiling SDS allowed to cool to room temperature)
and reprobed with an 18s rRNA probe. 18s rRNA levels
were measured by hybridization with an oligonucleotide
probe (5-ACGGTATCTGATCCGTCTTCGAACC-3) la-
beled with 32P-dCTP using terminal deoxytransferase
(Boehringer Mannheim Biochemicals, Indianapolis, IN).
After this, the membranes were subjected to the same wash-
ing procedures and image analysis as described.
Statistical Analysis. Gestational age and fetal and
placental weights and values from the enzymatic analysis
are reported as means ± SEM. Results from the phosphorus
imaging scanning, a ratio of ovine GDH mRNA expression
compared wih 18s rRNA expression, are reported as means
± SEM. Differences among groups were analyzed by Stu-
dent’s t test with significance set at P < 0.05.
Results
Tissue was collected at approximately 130 days of ges-
tation after fetal treatment. A 26-hr dexamethasone infusion
had no significant effects on fetal or fetal liver weights
(Table I).
The nucleotide sequence of ovine cDNA for GDH is
shown in Figure 1. The cDNA sequence for ovine GDH
(GenBank Accession number AY102935) exhibits 95.2,
91.7, and 90.9% homology with human (X07769, corre-
sponding to bp 192–672), rat (X14223), and murine
(X51081) sequences, respectively. In northern analysis, a
single transcript of approximately 2.8 kb was displayed,
which is in agreement with other published GDH message
data (24).
Dexamethasone infusion for 26 hr resulted in signifi-
cantly elevated GDH mRNA expression (P < 0.02; Fig. 2).
This increased GDH mRNA expression was accompanied
by an increase in mitochondrial GDH activity from 30.0 ±
7.4 to 58.2 ± 8.1 units of GDH activity/units of CS activity
(P < 0.03; Fig. 3). Moreover, there was a significant corre-
lation between GDH mRNA expression and GDH activity
(P < 0.001, r2  0.52; Fig. 4).
Discussion
These results demonstrate that under the influence of a
fetal dexamethasone infusion near term, sufficient to induce
parturition, the expression and activity of GDH in the fetal
liver is increased. GDH is exclusively located in the mito-
chondrial matrix and catalyzes the reaction:
glutamate + NAD+ + H2O ←→
-ketoglutarate + NH4 + NADH + H+
The equilibrium coefficient of this reaction is 1∼10 × 10−14,
which strongly favors glutamate production or what is
termed the reverse reaction (2). Together with recently pub-
lished data demonstrating that fetal dexamethasone infusion
decreases fetal glutamate output (13), the results reported
here demonstrate that the activity of GDH is increased and
altered to favor the forward reaction, that is, the production
of -ketoglutarate and associated reductive units. This
dexamethasone-induced change in GDH activity could, in
the normal course of events, be ascribed to the increased
need for citric acid cycle intermediates for glycogen syn-
thesis. In the fetal sheep, glucocorticoid infusions have been
demonstrated to increase fetal liver glycogen concentrations
(25), presumably through glucogenic enzymes such as GDH
and cytosolic phosphoenolpyruvate carboxykinase, changes
that occur naturally as parturition approaches.
The observation of increased hepatic GDH mRNA ex-
pression after fetal infusion of dexamethasone is the first
Table I. Placenta and Fetal Parameters in Control,
(5) and Dexamethasone, (7) Infused Fetus Near
Term (130 Days of Gestation). Values are Mean
± SEM
Control Dexamethasone
Gestational
age (days) 130 ± 2 130 ± 2
Placental
weight (g) 306.5 (n = 2) 370.8 ± 25.8 (n = 4)
Fetal weight (g) 2937.8 ± 322.2 3247.7 ± 207.3
Fetal liver
weight (g) 116.8 ± 11.0 103.1 ± 5.0
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report of in utero alterations in liver enzymatic activity in
the fetal sheep relative to glutamine/glutamate metabolism.
Glucocorticoid-induced increases in hepatic GDH activity
reported in this study are similar to those found previously
in adult (4) and fetal (3, 9, 24) rats, and the measured GDH
activity nearly doubled in this study after the 26-hr dexa-
methasone administration. In the rat, a relatively low activ-
ity of hepatic GDH has been described with activity increas-
ing just prior to birth (3, 24), where an increase in gluco-
corticoid concentration would be expected. Moreover,
maximal GDH mRNA expression levels are generally
reached 2 days prior to birth, declining to prebirth levels,
Figure 1. The sequence for sheep cDNA for
glutamate dehydrogenase (GenBank acces-
sion number AY102935) aligned with the se-
quence for human GDH (M20867).
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and then rising again to peak levels at 3–4 postnatal weeks
(24). Of additional interest is the observation that in the rat
placenta, as gestation advances, GDH activity actually de-
creases (9), suggesting a change in the placental metabolism
of glutamate and placental production of ammonia. This
change may occur as the placental role in fetoplacental
amino acid metabolism decreases and the fetus becomes the
major regulator of fetoplacental amino acid metabolism.
During the prenatal period, GDH mRNA expression is regu-
lated at both the translational level as well as at the pre-
translational level, whereas after birth, GDH expression is
thought to be regulated predominantly at the pretransla-
tional level (24). Studies in adult rats have shown that T3
treatment and cortisol increase the level of GDH, suggesting
hormonal regulation of this gene (5). The induction of GDH
activity by thyroid hormones is partly inhibited by blocking
de novo protein synthesis, suggesting that T3 is involved in
altering gene transcription as well as specific enzyme char-
acteristics (5). During fetal life, regulation of GDH through
thyroid hormone interactions have not yet been reported,
though the branched chain amino acids, leucine, isoleucine,
and valine are also reported to enhance GDH activity during
fetal life (26).
In conclusion, we have demonstrated that infusion of
dexamethasone induces significant increases in GDH mes-
sage expression and GDH activity. These data are consistent
with the in vivo studies, which have shown a redirection of
glutamine carbon away from net hepatic glutamate release
and into the citric acid cycle through the forward reaction
catalyzed by GDH, i.e., glutamate to oxoglutarate.
Figure 3. Hepatic GDH activity per citrate synthase activity for con-
trol and dexamethasone-treated fetuses after 26 hr of dexametha-
sone infusion. Values are means ± SEM.
Figure 2. Northern blot analysis of oGDH mRNA fetal hepatic levels of control and dexamethasone-infused fetuses after 26 hr of dexameth-
asone infusion. A single transcript was determined at approximately 2.8 kb. Quantification of the oGDH mRNA levels normalized to the signal
from 18s mRNA is shown below. Values are means ± SEM.
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